<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132871">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983878</url>
  </required_header>
  <id_info>
    <org_study_id>15045</org_study_id>
    <secondary_id>I4T-JE-JVCL</secondary_id>
    <nct_id>NCT01983878</nct_id>
  </id_info>
  <brief_title>A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer</brief_title>
  <official_title>A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate progression-free survival in participants with
      gastric or gastroesophageal junction cancer who have had disease progression following
      first-line therapy who undergo treatment with ramucirumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) Rate at 12 Weeks</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Measured Progressive Disease (PD) or Death from Any Cause (Estimated up to 12 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])</measure>
    <time_frame>Baseline to Measured PD or Death from Any Cause (Estimated up to 12 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate [DCR])</measure>
    <time_frame>Baseline to Measured PD or Death from Any Cause (Estimated up to 12 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Death from Any Cause (Estimated up to 12 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Ramucirumab Antibodies</measure>
    <time_frame>Baseline to 30 day Follow Up (Estimated up to 12 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab</measure>
    <time_frame>Cycle 1 Predose up to Cycle 2 Predose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Curve (AUC) of Ramucirumab</measure>
    <time_frame>Cycle 1 Predose up to Cycle 2 Predose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Ramucirumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol non compliance or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Ramucirumab</arm_group_label>
    <other_name>LY3009806</other_name>
    <other_name>IMC-1121B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed gastric carcinoma, including gastric
             adenocarcinoma or Gastroesophageal Junction (GEJ) adenocarcinoma

          -  Metastatic disease or locally recurrent, unresectable disease

          -  Measurable disease and/or evaluable disease

          -  Experienced disease progression during or within 4 months after the last dose of
             first-line therapy for metastatic disease, or during or within 6 months after the
             last dose of adjuvant therapy

          -  Life expectancy of at least 3 months

          -  Resolution to Grade less than or equal to 1 by the National Cancer Institute Common
             Terminology Criteria for Adverse , Version 4.03, of all clinically significant toxic
             effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy

          -  Eastern Cooperative Oncology Group performance status score of 0-1

          -  Has adequate organ function

          -  Must be postmenopausal, surgically sterile, or using effective contraception
             (hormonal or barrier methods), if sexually active

          -  Female participants of childbearing potential must have a negative serum or urine
             pregnancy test within 7 days prior to enrollment

        Exclusion Criteria:

          -  Documented and/or symptomatic brain or leptomeningeal metastases

          -  Bone metastases

          -  Experienced Grade 3/4 gastrointestinal (GI)  bleeding within 3 months prior to
             enrollment

          -  Experienced any arterial thromboembolic event within 6 months prior to enrollment

          -  Ongoing or active significant infection, symptomatic congestive heart failure (CHF),
             unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia,
             uncontrolled thromboembolic or hemorrhagic disorder, or any other serious
             uncontrolled medical disorders in the opinion of the investigator

          -  Ongoing or active psychiatric illness or social situation that would limit compliance
             with study requirements

          -  Blood pressure in abnormal range despite standard medical management

          -  Has a serious or nonhealing wound, ulcer, or bone fracture

          -  Received chemotherapy, radiotherapy, immunotherapy, or targeted therapy for gastric
             cancer

          -  Received any investigational therapy within 30 days prior to enrollment

          -  Undergone major surgery within 28 days prior to enrollment, or subcutaneous venous
             access device placement within 7 days prior to enrollment

          -  Received prior therapy with an agent that directly inhibits vascular endothelial
             growth factor (VEGF) or vascular endothelial growth factor receptor 2 (VEGFR-2)
             activity (including bevacizumab), or any anti-angiogenic agent

          -  Receiving chronic therapy with nonsteroidal anti-inflammatory drugs or receiving
             other antiplatelet agents. Aspirin use at doses up to 325 milligrams per day is
             permitted

          -  Has elective or planned major surgery to be performed during the course of the
             clinical study

          -  Has a known allergy to any of the treatment components

          -  Pregnant  or breastfeeding

          -  Have positive test results for human immunodeficiency virus, hepatitis B, or
             hepatitis C antibodies

          -  Known alcohol or drug dependency

          -  Previous or concurrent malignancy except for basal or squamous cell skin cancer
             (nonmelanoma) and/or pre-invasive carcinoma of the cervix, mucosal gastrointestinal
             or uterine carcinoma, or other solid tumors treated curatively and without evidence
             of recurrence for at least 3 years prior to enrollment

          -  Currently enrolled in a clinical trial involving an investigational product or
             non-approved use of a drug or device (other than the study drug/device used in this
             study), or concurrently enrolled in any other type of medical research judged not to
             be scientifically or medically compatible with this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>224-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka-Shi</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
